Sequence-Directed Transcriptional Silencing Using Gamma Peptide Nucleic Acids.

Direct targeting of genomic DNA represents a transformative strategy for transcriptional silencing, overcoming the transient effects and limited genomic access of antisense therapies. This chapter reviews γ-substituted peptide nucleic acids (γPNAs), with enhanced DNA-binding affinity and solubility, engineered to overcome these barriers. The tail-clamp γPNA design, incorporating Watson-Crick and Hoogsteen base-pairing domains, enables invasion of double-stranded DNA, while conjugation to a nuclear localization signal (NLS) ensures efficient cellular uptake and nuclear delivery. Focusing on the c-Myc oncogene, we detail methodology for the synthesis of γPNA-NLS conjugates targeting the c-Myc promoter to block transcription factor binding. Methods include gel shift and PCR amplicon assays to validate sequence-specific DNA binding, qRT-PCR to quantify c-Myc and downstream EZH2 mRNA suppression, and γH2AX foci and comet assays to assess genotoxicity. As examples, we summarize the results demonstrating robust transcriptional repression of c-Myc and minimal DNA damage, highlighting the therapeutic safety and efficacy of γPNAs. Here we describe a comprehensive platform that integrates rational γPNA-NLS design with functional validation, establishing a scalable and precise strategy for antigene therapy application.